@article{10818/43543,
year = {2018},
month = {2},
url = {http://hdl.handle.net/10818/43543},
abstract = {This study describes the development of an immunosensory label-free quantification methodology based on surface plasmon resonance (SPR) and its applicability in measuring/evaluating therapeutic drug monitoring (TDM) of anti-TNF-α monoclonal antibody (adalimumab) in rheumatoid arthritis (RA) patients. The experimental parameters evaluated in this study were immobilising ligands by pre-concentration assays, sensor surface regeneration, ascertaining the method’s sensitivity and correlating the results from quantifying plasma samples by ELISA immunoassay. The results showed that TNF-α quantification values (in RU) were significantly different when comparing patients (~50–250 RU) to controls (~10–20 RU). Likewise, there was 0.97 correlation for patients and 0.91 for healthy volunteers using SPR and ELISA comparison methodologies. SPR immunosensory detection provided a precise, sensitive strategy, along with real-time determination, for quantifying adalimumab, having great potential for clinical routine regarding TDM.},
publisher = {Sensors (Basel)},
keywords = {Biological drug},
keywords = {Therapeutic drug monitoring (TDM)},
keywords = {Optical biosensor},
title = {Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor},
doi = {10.3390/s18030691},
author = {Bustos, Rosa Helena and Zapata, Carlos and Esteban Mancera, Efraín Arsenio and García Casallas, Julio César and Jáuregui, Edwin},
}